Shares of Biogen Inc. (NASDAQ: BIIB - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirty-three research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, eighteen have assigned a buy recommendation

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

BlackRock Inc. bought a new stake in Biogen Inc. (NASDAQ: BIIB) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,985,736 shares of the biotechnology company's stock, valued at approximately $3,453,878,000. BlackRock Inc. owned approximately 10.82% of Biogen as of its

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.

Amundi increased its stake in Biogen Inc. (NASDAQ: BIIB) by 38.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 790,827 shares of the biotechnology company's stock after buying an additional 218,398 shares during the period. Amundi owned about 0.54%

It handily beat analyst estimates on both the top and bottom lines. Investors didn't even mind a cut in adjusted net income guidance.

Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

Biogen Inc. (NASDAQ:BIIB) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96.

Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.